Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
21 hedge funds and large institutions have $1.12M invested in Biocept, Inc. in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.08% less ownership
Funds ownership: 8.3% → 8.22% (-0.08%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
28% less capital invested
Capital invested by funds: $1.56M → $1.12M (-$436K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$64.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.4K |
| 3 |
VF
Virtu Financial
New York
|
+$28.3K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$20.2K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$22.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$14K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
BIOC Hedge Fund Activity: Q2 2018 in Review
21 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q2 2018, worth a combined $1.12M — down 28% from $1.56M a quarter earlier.
Fund positioning in BIOC was balanced in Q2 2018: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Barclays, adding an estimated $64.8K. The largest seller was Federation des caisses Desjardins du Quebec, cutting an estimated $22.3K.
- 21 institutional investors held Biocept, Inc. (BIOC) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.12M of Biocept, Inc. stock for Q2 2018, down 28% quarter-over-quarter.
- 3 funds opened new Biocept, Inc. positions in Q2 2018 and 3 closed out, a net change of 0 holders.
- The largest Biocept, Inc. buyer in Q2 2018 was Barclays, an estimated $64.8K added.
- The largest Biocept, Inc. seller in Q2 2018 was Federation des caisses Desjardins du Quebec, an estimated $22.3K sold.
Based on aggregated 13F filings for Q2 2018.